Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00456118|
Recruitment Status : Completed
First Posted : April 4, 2007
Last Update Posted : August 13, 2018
We have recently demonstrated that maternofetal alloimmunization was not limited to blood cells: maternal alloimmunization against a glomerular podocyte antigen expressed by the placenta can induce neonatal membranous glomerulonephritis.
Early recurrent pregnancy losses, preeclampsia and intervillositis are obstetrical pathologies which share an anomaly of placentation. Pathophysiology of these diseases is not yet fully understood; nevertheless the hypothesis of an incompatibility between mother and child is often mentioned. The aim of this project is to detect and study the cases of recurrent pregnancy losses, preeclamspia and intervillositis which could be induced by tissular maternofetal alloimmunization.
Materials and methods:
Patients suffering from recurrent pregnancy losses of unknown origin, preeclamspia or intervillositis will be included in this project. Mothers' sera will be studied by indirect immunofluorescence and Western Blot on placental biopsies from different origins and gestational ages. This stage will enable us to detect possible maternal allo-antibodies. After detecting and revealing antibodies, nature of the target antigen will be identified by immunoprecipitation of placental extracts, using the positive sera. Immunoprecipitation will be followed by a mass spectrometry analysis of detected proteins.
This study will enable us:
- to detect new cases of tissular maternofetal alloimmunization
- to improve our knowledge of mechanisms leading to anomalies of placentation
- to carry out a specific, preventive therapeutic approach for cases induced by tissular alloimmunization.
Recurrent pregnancy losses, Preeclampsia, Intervillositis, maternofetal alloimmunization.
|Condition or disease|
|Recurrent Pregnancy Losses Preeclampsia Intervillositis|
|Study Type :||Observational|
|Actual Enrollment :||83 participants|
|Official Title:||Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||December 2009|
60 womens for repeated miscarriages will be included
70 women for pre-eclampsia will be included
20 women for intervillites will be included
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00456118
|Bordeaux University Hospital|
|Bordeaux, France, 33076|
|LIMOGES University Hospital|
|Limoges, France, 87042|
|Saint Antoine Hospital|
|Paris, France, 75012|
|Paris, France, 75020|
|Paris, France, 75571|
|South Reunion Hospital|
|Saint Pierre, France, 97448|
|Toulouse University Hospital|
|Toulouse, France, 31059|
|Principal Investigator:||Vincent GUIGONIS, MD||University Hospital, Limoges|